Hong Kong: Jiangsu Recbio Technology to raise HK$765m with IPO

Jiangsu Recbio Technology, an China-based vaccine company with a focus on HPV vaccines, is selling 30.9 million H shares on the Hong Kong stock exchange at a fixed price of HK$24.80 per share to raise HK$765m (US$97.8m). Founded in 2012, Recbio is a vaccine company dedicated to the research, development and commercialization of subunit vaccines….

You must be a HMI Subscriber to view this content.

Subscribe Now »